Bi- and tricyclic indazole-substituted 1,4-dihydropyridine derivatives and uses thereof

US8759341B2 · kind B2 · utility

Assignee

• Bayer Intellectual Property GmbH · DE

Inventors

• Martin Michels
• Markus Follmann
• Alexandros Vakalopoulos · Hilden, DE
• Katja Zimmermann · Mülheim an der Ruhr, DE
• Mario Lobell · Wuppertal, DE
• Nicole Teusch · Uerdingen, DE
• Shendong Yuan · San Ramon, US

Key dates

• Filing date: Feb 5, 2010
• Grant date: Jun 24, 2014
• Expiry date: Mar 11, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D498/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention relates to novel bi- and tricyclic indazole-substituted 1,4-dihydropyridine derivatives having protein tyrosine kinase inhibitory activity, to a process for the manufacture thereof and to the use thereof for the treatment of c-Met-mediated diseases or c-Met-mediated conditions, particularly cancer and other proliferative disorders.